Rallybio Corp (RLYB): Cash & Equivalents
$31.37M
As of 2025-12-31
$92.85M
As of 2026-06-30
-18.0%
3-year compound annual growth
-25.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.37M | +125.7% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $13.90M | -43.2% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $24.49M | -57.0% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $56.96M | -67.5% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $175.33M | +25.0% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $140.23M | n/a | 2022-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Rallybio Corp (RLYB) | 2025-12-31 | $31.37M | +125.7% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $52.77M | n/m |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $54.19M | -5.6% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.51M | -9.0% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $24.71M | +57.4% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $132.2K | n/m |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $28.18M | +55.7% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $28.41M | -4.8% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
Compare RLYB, RFL, STTK, SXTP side by side · Screen every company in Pharmaceutical Preparations ↗